David A. Sallman, MD - Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens and Boosting Efficacy in Challenging AML Subtypes

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GFF865. CME/EBAH/AAPA/IPCE credit will be available until January 4, 2027.

Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.

Disclosure information is available at the beginning of the video presentation.